Squarepoint’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-99,559
| Closed | -$899K | – | 5053 |
|
|
2025
Q4 | $899K | Buy |
99,559
+83,175
| +508% | +$622K | ﹤0.01% | 2711 |
|
|
2025
Q3 | $51K | Sell |
16,384
-84,251
| -84% | -$223K | ﹤0.01% | 4226 |
|
|
2025
Q2 | $215K | Buy |
+100,635
| New | +$163K | ﹤0.01% | 3937 |
|
|
2025
Q1 | – | Sell |
-62,990
| Closed | -$138K | – | 5496 |
|
|
2024
Q4 | $138K | Sell |
62,990
-8,820
| -12% | -$20K | ﹤0.01% | 4605 |
|
|
2024
Q3 | $157K | Sell |
71,810
-4,729
| -6% | -$10.9K | ﹤0.01% | 3771 |
|
|
2024
Q2 | $177K | Buy |
76,539
+38,524
| +101% | +$160K | ﹤0.01% | 3694 |
|
|
2024
Q1 | $209K | Sell |
38,015
-190,474
| -83% | -$871K | ﹤0.01% | 3592 |
|
|
2023
Q4 | $564K | Buy |
+228,489
| New | +$2.17M | ﹤0.01% | 2914 |
|
|
2023
Q3 | – | Sell |
-10,087
| Closed | -$331K | – | 4298 |
|
|
2023
Q2 | $331K | Sell |
10,087
-19,166
| -66% | -$661K | ﹤0.01% | 2906 |
|
|
2023
Q1 | $980K | Sell |
29,253
-32,714
| -53% | -$1.27M | ﹤0.01% | 1903 |
|
|
2022
Q4 | $2.03M | Buy |
+61,967
| New | +$1.84M | 0.01% | 1356 |
|
Other funds holding VTYX
Squarepoint's VTYX Position: Q1 2026 in Review
Squarepoint sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 99,559 shares — an estimated $899K sold.
Squarepoint first reported a position in VTYX in Q4 2022 and held it in 11 quarters. The position peaked at $2.03M in Q4 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Squarepoint reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 99,559 Ventyx Biosciences shares in Q1 2026, an estimated $899K.
- Squarepoint first reported a position in Ventyx Biosciences in Q4 2022 and held it in 11 quarters.
- Squarepoint's Ventyx Biosciences position peaked at $2.03M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.